Physician profile
Matthew E Nadler
NPI 1063414225
$5,139.56
in general payments reported to CMS, 2019-2025
31 companies · $646 in 2025
The $646 reported for 2025 was less than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,261 · 2020: $307 · 2021: $180 · 2022: $24.09 · 2023: $350 · 2024: $372 · 2025: $646.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,368.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,368.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $905.93 | 2019 | |
| Boston Scientific Corporation | $827.58 | 2019-2024 | Wavewriter Alpha Prime 16 |
| Saluda Medical Americas, INC. | $494.24 | 2025 | Evoke |
| Amgen INC. | $470.70 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $318.55 | 2019-2021 | |
| Daiichi Sankyo INC. | $236.95 | 2019 | |
| Bioness INC | $200.58 | 2019 | |
| Medtronic USA, INC. | $199.97 | 2019 | |
| Tersera Therapeutics LLC | $180.70 | 2019 | |
| Spr Therapeutics, INC | $156.98 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $146.78 | 2019 | |
| Mdd US Operations, LLC | $139.75 | 2019-2020 | |
| Abbott Laboratories | $117.90 | 2019 | |
| Stimwave Technologies Incorporated | $100.00 | 2019 | |
| Nevro Corp. | $87.83 | 2019-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $77.56 | 2019-2025 | Belbuca, Xtampza |
| Globus Medical, INC. | $74.52 | 2025 | Senza |
| Allergan, INC. | $67.88 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $56.01 | 2019 | |
| Abbvie INC. | $34.10 | 2021 | |
| Painteq LLC | $33.78 | 2023 | Painteq |
| Eisai INC. | $32.62 | 2021 | |
| Pfizer INC. | $30.17 | 2021 | |
| Supernus Pharmaceuticals, INC. | $26.16 | 2019-2021 | |
| Redhill Biopharma INC. | $24.60 | 2021 | |
| Alexion Pharmaceuticals, INC. | $23.44 | 2025 | Strensiq |
| Shionogi INC | $22.55 | 2019 | |
| Virtus Pharmaceuticals LLC | $14.25 | 2021 | |
| Pernix Therapeutics Holdings, INC. | $13.31 | 2019 | |
| Sentynl Therapeutics, INC. | $12.11 | 2019 | |
| Fidia Pharma USA INC. | $12.06 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Nadler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.